Showing 5581-5590 of 9771 results for "".
- Duobrii Lotion for Plaque Psoriasis Hits Shelveshttps://practicaldermatology.com/news/duobrii-lotion-for-plaque-psoriasis-hits-shelves/2460079/Ortho Dermatologics’ Duobrii (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, is now available. Approved by the U.S. Food and Drug Administration on April 25, 2019, Duobrii is the first and only topical lotion that contains a uniq
- FDA Clears Allergan's CoolTone Devicehttps://practicaldermatology.com/news/fda-clears-allergans-cooltone-device/2460075/The FDA has cleared Allergan plc's CoolTone device for improvement of abdominal tone, strengthening of the abdominal muscles, and development for firmer abdomen. CoolTone is also indicated for strengthening, toning and firming of buttocks and thighs. “By partnering with A
- Sonrei Sea Clearly Gel Sunscreens Launchhttps://practicaldermatology.com/news/sonrei-sea-clearly-gel-sunscreens-launch/2460070/A new eco-friendly, gel-based sunscreen line from Sonrei, LLC is now available. “Crafted for every kind,” Sonrei is driven by a commitment of bringing to market a translucent broad-spectrum SPF with environmental principles at the core, the company says. Sonrei Sea Clearly T
- Novartis: New Data Show Cosentyx Has Durable Response Across Psoriatic Diseasehttps://practicaldermatology.com/news/novartis-new-data-show-cosentyx-has-durable-response-across-psoriatic-disease/2460068/A new comprehensive analysis shows the long-term efficacy and safety of secukinumab in multiple manifestations of psoriatic disease, including moderate-to-severe plaque-type, nail and palmoplantar psoriasis, psoriatic arthritis and ankylosing spondylitis. Data are derived from key Phase 3, random
- Lilly: 5-Year Sustained Efficacy and Safety Results for Taltz in Plaque Psoriasis at WCDhttps://practicaldermatology.com/news/lilly-5-year-sustained-efficacy-and-safety-results-for-taltz-in-plaque-psoriasis-at-wcd/2460066/Patients with moderate- to severe plaque psoriasis who continued to receive Taltz® (ixekizumab) maintained high levels of skin clearance with no unexpected safety outcomes for up to five years of treatment, according to new data Eli Lilly and Company is presenting at the World Congress of Der
- Skin Metabolomics: Estee Lauder Presents New Research at WCDhttps://practicaldermatology.com/news/skin-metabolomics-estee-lauder-presents-new-research-at-wcd/2460063/The Estée Lauder Companies Inc.Research & Development (R&D) team will present data focused on new findings in skin metabolomics, skin defense, ingredient science, and anti-aging research at the 2019 World Congress of Dermatology (WCD) in Milan, Italy from June 10 -15.
- Advanced Dermatology and Cosmetic Surgery Acquires Advanced Dermatology of Southern Marylandhttps://practicaldermatology.com/news/advanced-dermatology-and-cosmetic-surgeryacquires-advanced-dermatology-of-southern-maryland/2460057/Advanced Dermatology and Cosmetic Surgery (ADCS) has acquired the dermatology practice of Dr. Robyn James with locations in Fort Washington and La Plata, MD. Advanced Dermatology of Southern Maryland (ADSM), will continue to be led by Dr. James and Dr. Jeffrey Weddington, dermatologists who have
- Water's Edge Dermatology Acquires Coast Dermatologyhttps://practicaldermatology.com/news/waters-edge-dermatology-acquires-coast-dermatology/2460055/Water's Edge Dermatology, a provider of comprehensive dermatology services through 37 Florida locations, has acquired a controlling interest in Coast Dermatology, a medical/cosmetic dermatology practice in Venice, Florida. Terms of the transaction were not disclosed. This transactio
- BTL Taps Drew Barrymore as First Emsculpt Celebrity Ambassadorhttps://practicaldermatology.com/news/btl-taps-drew-barrymore-as-first-emscuplt-celebrity-ambassador/2460052/Drew Barrymore is Emsculpt's first celebrity ambassador. Through her partnership with Emsculpt, the actress and lifestyle mogul will share her treatment experience and results with media and on her social media channels. Ba
- FDA Approves Sorilux for Adolescent Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-sorilux-for-adolescent-plaque-psoriasis/2460039/The FDA has approved Mayne Pharma Group Limited's Sorilux (calcipotriene) Foam, 0.005% in adolescents 12 years and older. The FDA approved Sorilux in 2010 based on evidence from two eight-week placebo controlled clinical trials in patients with mild to moderate plaque psoriasis of t